

REGISTERED CHARITY NUMBER 1157147

**REPORT OF THE TRUSTEES AND
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31ST MARCH 2025
FOR
LEUKAEMIA BUSTERS (the CIO)**

Leukaemia Busters
MP3, Southampton General Hospital
Southampton Hampshire SO16 6YD

LEUKAEMIA BUSTERS
CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31ST MARCH 2025

	Page
Report of the Trustees	1 to 6
Independent Examiner's Report	7
Statement of Financial Activities	8
Balance Sheet	9
Notes to the Financial Statements	10 to 15

LEUKAEMIA BUSTERS
REPORTS OF THE TRUSTEES
FOR THE YEAR ENDED 31ST MARCH 2025

The Trustees present their report with the financial statements of the charity for the year ended 31st March 2025. The Trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015).

OBJECTIVES AND ACTIVITIES

Objectives and aims

Leukaemia Busters was established as a Charitable Incorporated Organisation (CIO) formed under a constitution dated 21st May 2014. Prior to this date Leukaemia Busters operated as a Charitable Trust (Registered Charity No. 1010957) that was registered with the Charity Commission on the 7th April 1992. The objectives of the charity are to relieve patients with leukaemia, lymphoma and other blood-related cancers through funding the pursuit of pure and translational scientific research aimed at the development of new improved therapies for these malignant diseases. The objective has in the past been achieved through research conducted in our dedicated research laboratory, The Simon Flavell Leukaemia Research Laboratory based at Southampton General Hospital. The charity's vision is a world in which leukaemia and related conditions are safely, quickly and completely cured and our mission is to fund and conduct research focused on providing antibody-based treatments that will provide this for leukaemia patients.

The Trustees have considered the Charity Commission's latest general guidance on public benefit when reviewing our aims and objectives and planning future activities and are satisfied that our main research activities meet requirements.

We pursue a research portfolio that has a translational value; that is research that is intended to yield practical benefits for patients through the development of novel treatments based on antibodies or other similar molecules. Unlike many medical research charities, Leukaemia Busters has in the past raised funds for direct application by its own scientists in its own laboratory in Southampton, and for collaborations with major national and overseas institutions under the management of the charity's scientific directors. In this way we have been able to hold firm to on-going investment in promising lines of research that meet our core objectives without our research having to compete for grant awards from external bodies whilst still maintaining scientific excellence through exhaustive independent peer review of our publications and scientific work.

Research activities

There have been some major changes at the charity following the closure of the charity's Simon Flavell Leukaemia Research Laboratory at Southampton General Hospital at the end of 2023. As reported in the previous year's annual trustees report this was a situation beyond the charity's control as the University of Southampton and University Hospital Southampton authorities required closure of our laboratories in order to carry out their own re-development plans for the site.

Despite this major blow to the charity's pursuit of research for the benefit of patients with haematological cancers the charity can look back with considerable satisfaction at the achievements made in the charity's laboratories over the 35 years it was active. The experimental and clinical findings made by our scientists during this time have contributed to the exploration of new antibody-based treatments for leukaemia and other blood related cancers and will continue to have a positive impact for many years ahead.

Following this major change of circumstances the Trustees have given serious thought and sought advice as to the direction the charity should now take. The possibility of establishing another laboratory at an alternative site was considered but discounted as being beyond the charity's currently available resources. After various consultations and discussions with other charities that have similar objectives, the Trustees took the decision to create research fellowship awards to support young scientists at academic institutions in the UK. These fellowships will be styled as "Simon Flavell Early Career Research Fellowships" as a tribute to the memory of ten-year-old Simon who died in 1990 with an incurable form of leukaemia.

The Trustees see this as the most cost-effective way of delivering high quality research specifically to be undertaken by early career scientists in university, hospital or other non-profit institutions for research work on immunotherapeutic approaches for the treatment of haematological malignancies. The Trustees consider that support of talented young scientists at an early stage in their career is of paramount importance to ensure a nurturing of the next generation of talented scientific minds who will become the research leaders of the future.

LEUKAEMIA BUSTERS
REPORTS OF THE TRUSTEES
FOR THE YEAR ENDED 31ST MARCH 2025

The Trustees are now actively working towards setting up a collaboration agreement with the London-based charity Children with Cancer UK (CwCUK), Registered Charity No.298405 to jointly fund early career research fellowships. Both CwCUK and Leukaemia Busters charities share similar aims and objectives and have similar foundation stories; both having been established by parents of children with leukaemia. The collaboration and sharing of fellowship costs between the charities will give a greater scope for funding opportunities in future. A call for applications for the first fellowship is expected to go out by or before early 2026. Research proposals received following the call will be subjected to independent peer review by both charities and awards only made to those that are the most innovative, scientifically sound and relevant.

The creation of early career research fellowship scheme in collaboration with CwCUK is an exciting new venture for Leukaemia Busters and will ensure that in future we will remain at the forefront of funding cutting-edge research that continues to contribute to the discovery and development of novel immunotherapies for the direct benefit of patients with haematological malignancies.

ACHIEVEMENT AND PERFORMANCE

Charitable activities

The Trustees are committed to the running of the CIO with extremely low overhead costs. The charity does not employ expensive fundraisers or contracted third parties but instead relies on voluntary and community efforts to raise funds. The Trustees continue to improve and refine, where necessary, good governance practices without adding an unnecessary burden to operating costs. The current trustees are totally committed to maintaining and improving the income streams of the charity to ensure that it can meet its future objectives of funding and delivering potentially life-saving research for the benefit of patients with haematological malignancies. To this end a new dynamic website kindly designed by web designers 21Six on a *pro bono* basis is in development and will reflect the changes and new direction at the charity. This together with an intensified and intelligent social media campaign is anticipated will boost the charity's income substantially.

The Trustees continue to maintain robust and reliable financial management systems that adhere to current regulations which have proven successful in the past. The Leukaemia Busters CIO has a clear sense of both purpose and direction that is driven by positive outcomes in the research it funds that is viewed as an important incremental step towards clinical benefits for patients. The Leukaemia Busters CIO retains a small but strong group of eight dedicated Trustees who between them share a wide range of skills that includes scientific, business, management and IT. As a charity funding medical research, we have an obligation to remain financially sound and prudent to ensure our goals are met. Our management systems are transparent and the Trustees exercise effective tight controls over the charity's money and assets.

We strongly believe that as an established local charity our clearly stated aims, well publicised achievements and prudent financial management have been the hallmarks of our success. The resultant low administrative overheads that we incur will allow us to truthfully tell organisations and individuals that more than ninety-six pence of every pound donated goes directly towards our charitable objectives. Maintaining our low running costs is absolutely essential if we are to project the right ethos to staff, beneficiaries and the wider public.

The Trustees are mindful of the charity's exposure to risk and have put in place checks and balances designed to minimise these. The charity adheres to all aspects of the General Data Protection Regulations (GDPR) and treats all personal data it collects with absolute confidentiality never sharing this with any third party or to be used in ways that might be considered as unethical.

The scientific research objectives of the charity have always been clearly stated. Increasing efforts will be made to attract funding from other charitable trusts, supportive academic institutions, government or other international sources. The majority of our funding to date has come from charitable trusts, charitable donations from individuals, other charitable organisations or legacies and we will continue to build on these sources.

Our financial reporting is scrutinised and approved by the Board of Trustees in twice yearly meetings. *Pro bono* support of our financial reporting is openly offered by Alison Powell ACMA, CGMA, CPFA, acting as our independent examiner. The Trustees are enormously grateful to her for her generosity in offering her free services to the charity. The Trustees have elected not to invest capital sums of money but to instead keep the charity's cash assets in bank accounts offering the highest current rate of the interest. Bank interest rates are regularly monitored and capital money moved as judged appropriate.

LEUKAEMIA BUSTERS
REPORTS OF THE TRUSTEES
FOR THE YEAR ENDED 31ST MARCH 2025

The charity's Trustees recognise the growing importance of legacies to our funding and see this as a priority for the future financial health of the charity. The Trustees are enormously grateful to those kind individuals who consider leaving the charity a legacy in their will in particular the late Elizabeth Ann Peters and the late Jean Emily Grant. Indeed, the Trustees are very grateful to all those loyal supporters, past and present, who have unstintingly supported the Leukaemia Busters in past years and hope that they will be able to continue to do so in the future to keep our work alive. It is these individuals who have made possible the lifesaving work we have conducted in the past.

We thank this year's significant contributors to fundraising for the charity's income this year, our busker John Breeze, Skydive, RJ Memorial Golf Day, Bournemouth, Eastleigh and Hamble Valley Rotary clubs. We also extend our sincere thanks to Brad Eynon and all staff at 21Six for their invaluable support in designing and maintaining the charity's website together with volunteer Tracey Forshaw. Last but not least we would like to thank all the Friends of Leukaemia Busters who as regular donors make an important and reliable contribution to the charity's income. The Trustees are optimistic that improving economic forecasts will ensure that future funding levels will safeguard the charity's work in funding high quality research that leads to the development of new and improved treatments for leukaemia and other blood cancers.

FINANCIAL REVIEW

Investment policy and objectives

In accordance with the CIO constitution the Trustees have the power to invest in any investments as they see fit to further the objectives of the CIO. The current policy is to adopt a low-risk investment strategy based on maximising income from bank deposits.

Financial position

During the year ended 31 March 2025 the CIO received donations and legacies totaling £47,886. The total fund balance at the end of the year amounted to £470,424.

The Trustees confirm that the CIO's assets are available and adequate to fulfil its obligations to meet all existing commitments.

Reserves Policy

The Trustees adopt a reserves policy of maintaining sufficient funds to meet the costs of approved research projects and to build funds to support work in the future. To ensure that this obligation is fulfilled the trustees have set aside £100,000, more than sufficient for one year's worth of research funding operations as its minimum reserve. The charity nevertheless seeks to establish break clauses in its grant approvals as a matter of prudence to ensure that the charity never becomes overextended.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document (a constitution) that constitutes a charitable incorporated organisation (CIO).

Governance position

The Trustees continue to retain and improve, where necessary, good governance practices without adding an unnecessary burden to operating costs.

Recruitment and appointment of new trustees

All trustees undergo a common selection and induction process. The Trustees have highlighted key areas of experience and competency that the trustee group needs to contain to be maximally effective. To function effectively the board needs to have a diverse range of skills covering areas such as IT, Business & Governance, Marketing & Media, Scientific & Medical. All new recruited trustees undergo the same application, selection and induction process, to make sure each is fit for purpose,

LEUKAEMIA BUSTERS
REPORTS OF THE TRUSTEES
FOR THE YEAR ENDED 31ST MARCH 2025

STRUCTURE, GOVERNANCE AND MANAGEMENT - continued

and are able to make a positive contribution to the running of the charity. We are delighted to welcome five new trustees during the period of this report with a diverse range of skills and know-how following their appointment to the board. These new trustees are as follows:

1. Dr Andrew Lane BSc PhD – an independent scientific consultant to Life Sciences companies in the UK and US. Prior to that Andy was a Commercial Director of the Native Antigen Company for more than 6 years. During 1989-1994 he was a head of monoclonal antibody development unit within a specialist Regional NHS laboratory, developing new antibodies for the diagnosis of leukaemia and lymphoma, and helped form the first clinical flow cytometry service in the south of England. He brings vital skills and know-how to the charity in promoting and protecting the charity's interests in the scientific area.
2. Mrs Angela Lane MSc – an independent scientific consultant with expertise in global commercial antibody manufacture, product development and licensing. Angie brings a wealth of skills in these areas that are highly relevant to the charity's needs and objectives.
3. Mr Shinderpal Shahi BSc MIET – a senior group IT manager and DPO at White & Company plc for 20 years. Shin has now been in this sector for over 40 years and has accumulated a diverse range of skills, working with Corporates, SME's and Charities that will undoubtedly be beneficial to the charity in the vital areas of security, governance and disaster recovery in today's world.
4. Mrs Serena Devon BA – an industry manager at Google, a company she has been with for over 7 years. Serena has a robust background in performance marketing. Serena brings digital marketing and social networking skills and know-how in these areas to the charity that are so important in today's age.
5. Mr Oliver Devon BA ACA – a UK Sales Director at Anheuser-Busch InBev., a company he has been with over 10 years. Ollie brings a new set of valuable skills to the charity that include corporate governance, management and financial skills. He is a sports enthusiast and in 2022 did the RideLondon-Essex 100 cycle ride for the charity. Prior to that he completed the London Marathon in 2017 for the charity and will do again in 2026.

Also during the period of this report, long standing supporter and trustee Mrs Jennie Sherborne MBE retired from the board after 15 years of invaluable service. The Board of Trustees is very grateful for her engaged and committed service to the charity and thanks her for her 15 years of service, her enthusiasm and generous commitment in her role as a Trustee and we wish her well in her retirement.

Organisational structure

The current board of eight trustees collectively provide the steerage and have full responsibility over the financial control of the charity with certain responsibilities designated to trustees possessing the appropriate skill set. Regular board meetings led by two co-chairs and frequent communications between trustees ensures that set tasks are undertaken effectively.

From the 1st September 2024 the charity has had no paid staff and has no plans for the foreseeable future to employ anyone unless this becomes necessary.

The Trustees have recently reviewed and amended, where necessary, their good governance practices including policies and procedures documentation. Overall, the Trustees consider that systems currently in place are in line with market best practice and the board follows the principles of the "Code of Good Governance".

Induction and training of new trustees

All potential new trustees are required to complete a standard application form detailing their skills and the benefits they will bring to the charity. All trustees are provided with the CIO governing document, a role description detailing their responsibilities, and Charity Commission and "Code of Good Governance" good practice guidelines. All appointees are invited to the board. The trustees are kept abreast of regulatory and general governance developments through internal communications, board presentations and other reference material supplied by the Charity Commission. All appointees are invited to attend a free charity induction and refresher training session on their legal duties and responsibilities as charity trustees kindly provided by at no cost to the charity by Trethowans LLP Southampton and Poole.

LEUKAEMIA BUSTERS
REPORTS OF THE TRUSTEES
FOR THE YEAR ENDED 31ST MARCH 2025

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Charity number

1157147

Principal address

c/o Southampton General Hospital
Mailpoint 3
Tremona Road
Southampton
Hampshire
SO16 6YD

Trustees

R W Sutcliffe Co-Chair
Dr D J Flavell Co-Chair
Dr S U Flavell
Mrs J Sherborne (Resigned 03/11/2024)
Dr A C Lane (Appointed 24/09/2024)
Mrs A M Lane (Appointed 24/09/2024)
S S Shahi (Appointed 24/09/2024)
Mrs S Devon (Appointed 24/09/2024)
O J Devon (Appointed 18/10/2024)

Independent Examiner

Alison Powell B.Sc. (Hons), ACMA, CGMA, CPFA

Bankers

HSBC Bank PLC
55 Above Bar Street
Southampton
SO14 7DZ

Nat West Bank PLC
68 Above Bar Street
Southampton
SO14 7DS

Virgin Money PLC
Sunderland
SR43 4JB

LEUKAEMIA BUSTERS
REPORTS OF THE TRUSTEES
FOR THE YEAR ENDED 31ST MARCH 2025

REFERENCE AND ADMINISTRATIVE DETAILS

Patrons

David and Thorunn Gower

Honorary Officers

Dr D J Flavell (Honorary Charity & Scientific Director)

Dr S U Flavell (Honorary Executive Scientific Director)

Fundraising Presidents

Harry and Sandra Redknapp

Ambassadors

Stewart Dunn

Lawrie McMenemy

Bruce Parker

Sally Taylor

Approved by order of the board of trustees on 08th September 2025 and signed on its behalf by:



.....
R W Sutcliffe – Co-Chair of Trustees

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF LEUKAEMIA BUSTERS

Independent examiner's report to the trustees of Leukaemia Busters

I report to the charity trustees on my examination of the accounts of Leukaemia Busters (the CIO) for the year ended 31st March 2025.

Responsibilities and basis of report

As the charity trustees of the CIO you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').


I report in respect of my examination of the CIO's accounts carried out under section 145 of the Act and in carrying out my examination I have followed all applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the CIO as required by section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Alison Powell ACMA, CGMA, CPFA

Date: ...10/09/2025.....

LEUKAEMIA BUSTERS

STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31ST MARCH 2025

	Notes	Unrestricted fund £	Restricted fund £	2025 Total funds £	2024 Total funds £
INCOME FROM					
Donations and legacies	2	41,453	-	41,453	123,067
Fundraising and Other income	3	13,833	-	13,833	27,600
Grants		-	-	-	-
Bank Interest	4	14,769	-	14,769	10,486
Total		70,055	-	70,055	161,153
EXPENDITURE ON					
Office and Administration		1,998	-	1,988	2,691
Fundraising Costs		809	-	809	41
Leukaemia research		63,576	-	63,576	110,138
Total		66,383	-	66,386	112,870
NET INCOME/(EXPENDITURE)		3,672	-	3,672	48,283
Transfers between funds		-	-	-	-
Net movement in funds		3,672	-	3,672	48,283
RECONCILIATION OF FUNDS					
Total funds brought forward		466,752	-	466,752	466,469
TOTAL FUNDS CARRIED FORWARD		470,424	-	470,424	466,752

The notes form part of these financial statements

LEUKAEMIA BUSTERS

**BALANCE SHEET
31ST MARCH 2025**

	Notes	Unrestricted fund £	Restricted fund £	2025 Total funds £	2024 Total funds £
FIXED ASSETS					
Tangible assets	9	839	-	839	1,292
CURRENT ASSETS					
Debtors		-	-	-	-
Cash in hand		469,651	-	469,651	467,930
		<u>469,651</u>		<u>469,651</u>	<u>467,930</u>
CREDITORS					
Amounts falling due within one year	10	(66)	-	(66)	(2,470)
		<u>469,585</u>	<u>-</u>	<u>469,585</u>	<u>465,460</u>
NET CURRENT ASSETS					
		<u>470,424</u>	<u>-</u>	<u>470,424</u>	<u>466,725</u>
TOTAL ASSETS LESS CURRENT LIABILITIES					
		<u>470,424</u>	<u>-</u>	<u>470,424</u>	<u>466,752</u>
NET ASSETS					
		<u>470,424</u>	<u>-</u>	<u>470,424</u>	<u>466,752</u>
FUNDS	11				
Unrestricted funds				470,424	466,752
Restricted funds				-	-
				<u>470,424</u>	<u>466,752</u>
TOTAL FUNDS CARRIED FORWARD				<u>470,424</u>	<u>466,752</u>

The financial statements were approved by the board of trustees and authorised for issue on 08th September 2025 and were signed on its behalf by:



.....
R W Sutcliffe – Trustee



.....
S U Flavell – Trustee

The notes form part of these financial statements

LEUKAEMIA BUSTERS

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR 31ST MARCH 2025

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Raising funds

Fund raising costs

Fund raising costs represent promotional expenses incurred by the CIO.

Promotional items

Promotional items are written off in the year of purchase.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery - 25% on cost

Taxation

The charity is exempt from tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the Trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Pension costs and other post-retirement benefits

The charity operates a defined contribution pension scheme. Contributions payable to the charity's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Bank Interest

Bank interest is accounted for at the time it is crystallised on the bank statement.

LEUKAEMIA BUSTERS

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR 31ST MARCH 2025

2. DONATIONS AND LEGACIES

	2025	2024
	£	£
Friendship scheme	7,820	7,988
In memoriam/bequests	7,608	7,463
Donation	16,394	29,116
Legacy income	9,631	78,500
Total	<u>41,453</u>	<u>123,067</u>

Summary of legacy income

	2025	2024
	£	£
The late Elizabeth Ann Peters	2,000	-
The late Dorothy Isabel Dewhurst	131	-
The late Dennis Heath	-	5,000
The late David Cosway	-	2,500
The late Anne Chapple	-	1,000
The late Jean Emily Grant	7,500	70,000
Total	<u>9,631</u>	<u>78,500</u>

3. OTHER TRADING ACTIVITIES

	2025	2024
	£	£
Events	6,433	27,600
Disposal of laboratory Equipment	2,000	-
Disposal of laboratory furniture	5,400	-
Total	<u>13,833</u>	<u>27,600</u>

Summary of Events

	2025	2024
	£	£
Bournemouth Half Marathon 2025	267	-
Skydive 2025	3,513	-
Hampshire Motocross Club 2023	-	25,042
Robert Meech London Marathon 2023	-	1,329
R J Williams Memorial Golf Day 2024	2,653	1,103
Scafell Pike walk	-	126
Total	<u>6,433</u>	<u>27,600</u>

4. INVESTMENT INCOME

	2025	2024
	£	£
Deposit account interest	<u>14,769</u>	<u>10,486</u>

LEUKAEMIA BUSTERS

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR 31ST MARCH 2025

5. TRUSTEES REMUNERATION AND BENEFITS

Two trustees were employed by the charity to manage its scientific research programme for the period ended 31st March 2025.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31st March 2025 nor for the year ended 31st March 2024.

6. STAFF COSTS

The average monthly number of employees during the year was as follow:

	2025	2024
	2	4
Scientific staff		

No employees received emoluments in excess of £60,000

7. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted fund £	Restricted fund £	Total funds £
INCOME FROM			
Donations and legacies	123,067	-	123,067
Other trading activities	27,600	-	27,600
Grant income	-	-	-
Investment income	10,486	-	10,486
Total	161,153	-	161,153
EXPENDITURE ON			
Raising funds	2,732	-	2,732
Charitable activities			
Leukaemia research	110,138	-	110,138
Total	112,870	-	112,870
NET INCOME/(EXPENDITURE)	48,283	-	48,283
Transfer between funds	-	-	-
Net movement in funds	48,283	-	48,283
RECONCILIATION OF FUNDS			
Total funds brought forward	418,469	-	418,469
TOTAL FUNDS CARRIED FORWARD	466,752	-	466,752

LEUKAEMIA BUSTERS

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR 31ST MARCH 2025

8. RESTRICTED FUND

The restricted fund includes the following:

Fixed assets

These have been written down in line with the accounting policy.

9. TANGIBLE FIXED ASSETS

	Plant and machinery £
COST	
At 1 st April 2024	43,011
Additions	257
	<hr/>
At 31 st March 2025	43,268
 DEPRECIATION	
At 1 st April 2024	41,719
Charge for year	710
	<hr/>
At 31 st March 2025	42,429
 NET BOOK VALUE	
At 31 st March 2025	<hr/> 839
At 31 st March 2024	<hr/> 1,292

LEUKAEMIA BUSTERS

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR 31ST MARCH 2025

10. CREDITORS AMOUNTS FALLING DUE WITHIN ONE YEAR

	2025 £	2024 £
Trade creditors	66	50
Taxation and social security	-	1,727
Other creditors	-	693
	<u>66</u>	<u>2,470</u>

11. MOVEMENT IN FUNDS

	At 01/04/24 £	Net movement in funds £	Transfers between funds £	At 31/03/25 £
Unrestricted funds				
General fund	466,752	3,672	-	470,424
Restricted funds				
Restricted fund	-	-	-	-
TOTAL FUNDS	<u>466,752</u>	<u>3,672</u>	<u>-</u>	<u>470,424</u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	70,055	66,383	3,672
Restricted funds			
Restricted fund	-	-	-
TOTAL FUNDS	<u>70,055</u>	<u>66,383</u>	<u>3,672</u>

Comparatives for movement in funds

	At 01/04/23 £	Net movement in funds £	Transfers between funds £	At 31/03/24 £
Unrestricted funds				
General fund	418,469	48,283	-	466,752
Restricted funds				
Restricted fund	-	-	-	-
TOTAL FUNDS	<u>418,469</u>	<u>48,283</u>	<u>-</u>	<u>466,752</u>

LEUKAEMIA BUSTERS

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR 31ST MARCH 2025

11. MOVEMENT IN FUNDS - continued

Comparative net movement in funds, included in the above are follows:

	Incoming resources £	Resources expended £	Movement in fund £
Unrestricted funds			
General fund	161,153	112,870	48,283
Restricted funds			
Restricted fund	-	-	-
	<hr/>	<hr/>	<hr/>
TOTAL FUNDS	<u>161,153</u>	<u>112,870</u>	<u>48,283</u>

12. RELATED PARTY DISCLOSURES

There were no related transactions for the year ended 31st March 2025.